Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

This document reports that the Phase 1/2 study of MEDI-538 for chronic lymphocytic leukemia has been withdrawn. The sponsor is MedImmune LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• MEDI-538

Snippet

Sponsor: MedImmune LLC | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN